NuvoAir secures $11m funds from Hika Ventures for clinical trials platform
NuvoAir, the digital respiratory health care platform that helps manage asthma and chronic obstructive pulmonary disease (COPD), announced that it has secured $11 million in funding from UK-based Hikma Ventures to expand its patient-centric care and clinical trials platform. The company said that the money will be used to speed up its clinical services launch with risk-bearing providers and health plans. NuvoAir founder and CEO Lorenzo Consoli said that the company will focus more on treating complex COPD and asthmatic patients. Stressing on their patient-centric approach, Consoli also expressed hopes that their platform will benefit many.